State courts and MDLs are being used together as complementary forums in modern mass tort strategy—not as competing alternatives. Rather than following outdated advice to automatically consolidate everything into federal MDLs, sophisticated plaintiffs’ counsel now view state court filings as strategic pressure points that can accelerate settlements, enable faster trials, and create negotiating leverage that purely federal dockets cannot generate. The Johnson & Johnson talcum powder litigation illustrates this evolution: 67,100 cases pending in the federal MDL exist alongside California state court consolidation (JCCP No.
4872), where bellwether trials have actually progressed on a faster timeline, forcing settlement discussions that might have stalled in federal court alone. Legal experts now describe the choice between state and federal court as “materially incomplete” advice—the real strategy is deploying both simultaneously. State courts offer inherent advantages: juries drawn from state populations with stronger product liability traditions, judges with dedicated docket space (unlike overwhelmed federal MDL judges), and procedural rules that often permit faster discovery and trial schedules. When coordinated with federal MDLs rather than treated as afterthoughts, state court filings function as a critical multiplier effect in mass tort outcomes.
Table of Contents
- Why State Courts Have Become Strategic Leverage in MDL Litigation
- The Raw Numbers: How Many Cases Are Actually Split Between State and Federal Courts
- Active Major Cases Using State and Federal Coordination Right Now
- Procedural Tools That Enable State-Federal Coordination
- Strategic Advantages of the Dual-Forum Approach and Where It Falls Short
- Federal Rule of Civil Procedure 16.1 and Mandatory Coordination
- The McKivison Verdict and What $2.25 Billion in State Court Teaches the Entire Litigation Ecosystem
Why State Courts Have Become Strategic Leverage in MDL Litigation
For decades, attorneys treating mass tort claims viewed MDLs as the inevitable destination—a consolidation mechanism designed by federal judges to streamline thousands of similar cases. That framework missed a fundamental shift: state courts are no longer backwater forums for leftover claims. They’re now active players in settlement negotiations because they possess something federal MDLs structurally lack—genuine trial capacity and predictable scheduling. The federal court system carries an enormous burden. MDLs now represent nearly two-thirds of all private civil cases in federal court, with approximately 199,000 cases pending in MDLs nationally and 704,000 total cases filed across all MDLs since their inception. Federal judges managing these dockets face resource constraints that naturally favor settlements over trials.
State court judges, by contrast, maintain separate calendars with available trial slots. When a plaintiff’s team credibly demonstrates it will try cases in state court—and has already docketed them there—defense counsel’s cost calculus changes immediately. The threat of multiple state court trials with unpredictable juries shifts negotiating dynamics in ways that generic federal MDL status conferences cannot. This is not theoretical. In the Uber sexual assault MDL (currently 3,571 active federal cases), parallel litigation in california JCCP (679 cases) proceeded with a first trial scheduled for September 2025—months ahead of any federal MDL trial date. That real trial date forced settlement discussions that federal pretrial conferences had not produced. Defense counsel cannot ignore a concrete calendar date in state court, even when thousands of other cases remain parked in federal consolidation.
The Raw Numbers: How Many Cases Are Actually Split Between State and Federal Courts
Understanding the scale requires looking at current data. As of June 2026, approximately 704,000 total cases have been filed across all MDLs since they began, with 199,000 pending right now. However, these federal numbers tell only part of the story. In major active MDLs, a substantial portion of the universe has parallel state court dockets that do not appear in federal case counts. The Depo-Provera meningioma litigation provides precise documentation: the federal MDL-2698 contains 5,549 cases, but an additional 622 state court cases exist across Delaware (340), New York (119), California (91), and Minnesota (72). Those state cases are materially underrepresented in most analyses of the litigation, yet they occupy critical calendar space and trial capacity.
A similar pattern exists in GLP-1 vision loss claims (Ozempic/Wegovy)—the federal MDL-3094 shows 3,626 cases, but pending parallel litigation in Indiana and New Jersey state courts creates additional trial pressure. A major limitation of relying solely on federal MDL data is that it systematically undercounts the actual scale of mass tort claims; the real litigation is fragmented across jurisdictions, and that fragmentation is intentional strategy, not administrative chaos. product liability claims dominate MDL volume, accounting for approximately 95% of federal docket volume tied to MDLs. This concentration means that any significant plaintiff victory in a state court product liability case immediately impacts negotiations in hundreds or thousands of MDL cases. When McKivison v. Monsanto produced a $2.25 billion state court verdict in January 2024, that single decision from a jury outside the federal MDL system rippled through settlement talks nationwide—a warning sign that federal judges could not have credibly communicated to defense teams.
Active Major Cases Using State and Federal Coordination Right Now
The Johnson & Johnson talcum powder litigation remains the largest MDL by pending volume. The federal MDL-2738 contains 67,100 pending cases, yet California’s coordinated proceeding (JCCP No. 4872) operates in parallel with six bellwether ovarian cancer trials scheduled for November 2025. What’s notable: the state court trials are occurring on a measurably faster timeline than the federal counterpart, which has been pending since 2014. This speed differential is not coincidental.
State judges operate without the capacity constraints that federal MDL judges navigate, and California’s JCCP rules permit more aggressive discovery schedules. The defense team cannot simply wait out the federal docket when a credible threat of trial exists in state court months earlier. The Depo-Provera meningioma litigation (MDL-2698) demonstrates how state court proceedings can pressure general causation discovery. The federal MDL has progressed through expert disclosures, but a general causation hearing was scheduled for June 24-25, 2026—in state court, not federal court. That state hearing creates a concrete deadline that forces parties to finalize expert opinions and causation arguments faster than would occur in a federal track alone. Defense counsel must be prepared to defend causation in one forum while managing federal discovery in another, multiplying their litigation expense and complexity.
Procedural Tools That Enable State-Federal Coordination
The coordination mechanisms differ markedly between systems. California’s JCCP (Judicial Council Coordinated Proceedings) consolidates related cases filed in different counties within the state, creating a single judge and streamlined discovery. This is not an MDL—it’s a state-level consolidation tool that operates independently of federal MDL rules. When cases exist in both JCCP and federal MDL simultaneously, parties must navigate two separate procedural regimes, discovery schedules, and judge instructions. The administrative burden is significant, but the strategic advantage is also significant: a plaintiff can pursue aggressive discovery in state court while maintaining leverage in federal settlement discussions. Joint Special Masters represent another coordination mechanism. In cases like *In re Bextra & Celebrex Marketing* (MDL-1699), courts appointed a single special master with authority across all cases—in some instances, a retired federal judge given expanded mediation and discovery duties.
This individual oversees both federal MDL discovery and coordinates communication with state court judges in parallel litigation. The advantage is consistency in discovery rulings and reduced gamesmanship. The limitation is that neither state nor federal judge directly controls the process; instead, a third party manages procedures across jurisdictions, which can slow decisions and create interpretation disputes when state and federal courts diverge on admissibility or discovery scope. A warning: coordination tools require affirmative judicial cooperation. Not all state judges embrace early coordination with federal MDL judges; some view it as an intrusion on state court autonomy. In jurisdictions where judicial resistance is high, the coordination mechanisms break down, and parties face genuinely duplicative discovery, conflicting discovery orders, and procedural chaos. This is not rare—it occurs frequently in states where state court judges see their docket space as a competitive advantage rather than an opportunity for efficient case management.
Strategic Advantages of the Dual-Forum Approach and Where It Falls Short
Filing in state court creates genuine trial leverage because state juries can be materially different from federal juries in the same geographic region. Federal jurors are drawn from broader geographic pools and tend to be more defense-oriented in product liability cases. State court jurors, particularly in states with strong tort traditions, may view manufacturer liability more expansively. The defense team cannot dismiss state court filings as inconsequential; they represent actual trial risk with a materially different pool of decision-makers. However, the dual-forum strategy has critical limitations.
Plaintiffs’ counsel must have sufficient case volume in a state to make state court filing economically rational—filing one or two cases in state court creates no meaningful trial pressure and burns litigation resources pursuing duplicative discovery. Most successful state court strategies involve filing dozens or hundreds of cases in a single state or coordinated group of states. This requires capital, staffing capacity, and confidence in the state court’s willingness to consolidate or coordinate. Small plaintiff firms cannot execute this strategy; it demands resources comparable to federal MDL practice. Additionally, if a state court judge consolidates cases and then stays the proceedings pending federal MDL resolution, the state court filing becomes merely another queue in the federal consolidation, eliminating the timing advantage that made the state filing valuable in the first place.
Federal Rule of Civil Procedure 16.1 and Mandatory Coordination
Effective December 1, 2025, Federal Rule of Civil Procedure 16.1 became the first rule designed specifically for MDLs. It requires parties to report early on procedures for direct filing and coordination with state courts. This rule represents a formal recognition that state and federal litigation are now integrated parts of mass tort strategy, not separate tracks. Judges managing MDLs must now explicitly address state court coordination in initial case management conferences.
The practical impact: MDL judges can no longer ignore parallel state court litigation as outside their jurisdiction. Rule 16.1 permits—and arguably mandates—that federal judges establish procedures for communication with state court judges, sharing of discovery materials, and consistent treatment of bellwether cases across forums. Courts are also no longer tolerating cases “parked” in MDLs without supporting information; mandatory fact sheet compliance has tightened considerably, requiring plaintiffs to provide detailed factual allegations supporting each claim rather than generic allegations that satisfied older MDL practices. This change increases the burden on plaintiffs’ counsel to develop cases earlier, which can accelerate settlement discussions.
The McKivison Verdict and What $2.25 Billion in State Court Teaches the Entire Litigation Ecosystem
In January 2024, McKivison v. Monsanto produced a state court verdict of $2.25 billion in punitive damages for a single plaintiff’s glyphosate exposure claim. This verdict was rendered by a state jury, not a federal jury, and it was upheld through initial appeals. The verdict’s significance extends far beyond the single case: it demonstrated that state court juries—specifically, juries in state systems with strong product liability traditions—could render verdicts of historically unprecedented magnitude based on causation theories and punitive rationales that might fail in federal court.
The verdict immediately rippled through settlement negotiations in the federal MDL-2741 (Roundup/glyphosate litigation), which contained thousands of pending cases. Defense counsel could no longer credibly argue that punitive damages were unlikely or that state juries would not follow certain causation theories. The state court verdict became evidence—literal proof—that the litigation risk in state forums exceeded the risk in federal forums. This is why state court filings function as leverage: they generate trial outcomes that reshape entire negotiation landscapes, whereas federal MDL status conferences generate settlement demands without corresponding jury verdicts to validate the settlement request. The McKivison verdict proved that a single well-developed state court case can be more valuable to settlement discussions than years of federal MDL procedures without any actual jury verdict.
- —